O	0	10	Randomized
O	11	22	Multicenter
O	23	30	Placebo
O	30	31	-
O	31	41	Controlled
O	42	47	Trial
O	48	50	of
B-intervention	51	56	Omega
I-intervention	56	57	-
I-intervention	57	58	3
I-intervention	59	64	Fatty
I-intervention	65	70	Acids
O	71	74	for
O	75	78	the
O	79	86	Control
O	87	89	of
B-condition	90	99	Aromatase
I-condition	100	109	Inhibitor
I-condition	109	110	-
I-condition	110	117	Induced
I-condition	118	133	Musculoskeletal
I-condition	134	138	Pain
O	138	139	:
O	140	144	SWOG
O	145	150	S0927
O	150	151	.

O	152	167	Musculoskeletal
O	168	176	symptoms
O	177	180	are
O	181	184	the
O	185	189	most
O	190	196	common
O	197	204	adverse
O	205	212	effects
O	213	215	of
O	216	225	aromatase
O	226	236	inhibitors
O	237	238	(
O	238	241	AIs
O	241	242	)
O	243	246	and
O	247	250	can
O	251	257	result
O	258	260	in
O	261	270	decreased
O	271	278	quality
O	279	281	of
O	282	286	life
O	287	290	and
O	291	306	discontinuation
O	307	309	of
O	310	317	therapy
O	317	318	.

O	319	324	Omega
O	324	325	-
O	325	326	3
O	327	332	fatty
O	333	338	acids
O	339	340	(
O	340	342	O3
O	342	343	-
O	343	346	FAs
O	346	347	)
O	348	351	can
O	352	354	be
O	355	364	effective
O	365	367	in
O	368	378	decreasing
O	379	389	arthralgia
O	390	399	resulting
O	400	404	from
O	405	418	rheumatologic
O	419	429	conditions
O	430	433	and
O	434	442	reducing
O	443	448	serum
O	449	462	triglycerides
O	462	463	.

B-eligibility	464	469	Women
I-eligibility	470	474	with
I-eligibility	475	480	early
I-eligibility	480	481	-
I-eligibility	481	486	stage
I-eligibility	487	493	breast
I-eligibility	494	500	cancer
I-eligibility	501	510	receiving
I-eligibility	511	513	an
I-eligibility	514	516	AI
I-eligibility	517	520	who
I-eligibility	521	524	had
I-eligibility	525	526	a
I-eligibility	527	532	worst
I-eligibility	533	538	joint
I-eligibility	539	543	pain
I-eligibility	543	544	/
I-eligibility	544	553	stiffness
I-eligibility	554	559	score
I-eligibility	560	561	≥
I-eligibility	562	563	5
I-eligibility	564	566	of
I-eligibility	567	569	10
O	570	575	using
O	576	579	the
O	580	585	Brief
O	586	590	Pain
O	591	600	Inventory
O	600	601	-
O	601	606	Short
O	607	611	Form
O	612	613	(
O	613	616	BPI
O	616	617	-
O	617	619	SF
O	619	620	)
O	621	625	were
O	626	634	randomly
O	635	643	assigned
O	644	646	to
O	647	654	receive
O	655	661	either
O	662	664	O3
O	664	665	-
O	665	668	FAs
O	669	670	3
O	670	671	.
O	671	672	3
O	673	674	g
O	675	677	or
O	678	685	placebo
O	686	687	(
O	687	694	soybean
O	694	695	/
O	695	699	corn
O	700	703	oil
O	703	704	)
O	705	710	daily
O	711	714	for
O	715	717	24
O	718	723	weeks
O	723	724	.

O	725	735	Clinically
O	736	747	significant
O	748	754	change
O	755	758	was
O	759	766	defined
O	767	769	as
O	770	771	≥
O	772	773	2
O	773	774	-
O	774	779	point
O	780	784	drop
O	785	789	from
O	790	798	baseline
O	798	799	.

O	800	808	Patients
O	809	813	also
O	814	823	completed
O	824	831	quality
O	831	832	-
O	832	834	of
O	834	835	-
O	835	839	life
O	840	841	(
O	841	851	Functional
O	852	862	Assessment
O	863	865	of
O	866	872	Cancer
O	873	880	Therapy
O	880	881	-
O	881	890	Endocrine
O	891	899	Symptoms
O	899	900	)
O	901	904	and
O	905	915	additional
O	916	920	pain
O	920	921	/
O	921	930	stiffness
O	931	942	assessments
O	943	945	at
O	946	954	baseline
O	955	958	and
O	959	964	weeks
O	965	966	6
O	966	967	,
O	968	970	12
O	970	971	,
O	972	975	and
O	976	978	24
O	978	979	.

O	980	986	Serial
O	987	994	fasting
O	995	1000	blood
O	1001	1004	was
O	1005	1014	collected
O	1015	1018	for
O	1019	1024	lipid
O	1025	1033	analysis
O	1033	1034	.

O	1035	1040	Among
B-total-participants	1041	1044	262
O	1045	1053	patients
O	1054	1064	registered
O	1064	1065	,
B-total-participants	1066	1069	249
O	1070	1074	were
O	1075	1084	evaluable
O	1084	1085	,
O	1086	1090	with
B-intervention-participants	1091	1094	122
O	1095	1100	women
O	1101	1103	in
O	1104	1107	the
O	1108	1110	O3
O	1110	1111	-
O	1111	1113	FA
O	1114	1117	arm
O	1118	1121	and
B-control-participants	1122	1125	127
O	1126	1128	in
O	1129	1132	the
B-control	1133	1140	placebo
O	1141	1144	arm
O	1144	1145	.

O	1146	1154	Compared
O	1155	1159	with
O	1160	1168	baseline
O	1168	1169	,
O	1170	1173	the
B-outcome	1174	1178	mean
I-outcome	1179	1187	observed
I-outcome	1188	1191	BPI
I-outcome	1191	1192	-
I-outcome	1192	1194	SF
I-outcome	1195	1200	score
O	1201	1210	decreased
O	1211	1213	by
O	1214	1215	1
O	1215	1216	.
O	1216	1218	74
O	1219	1225	points
O	1226	1228	at
O	1229	1231	12
O	1232	1237	weeks
O	1238	1241	and
O	1242	1243	2
O	1243	1244	.
O	1244	1246	22
O	1247	1253	points
O	1254	1256	at
O	1257	1259	24
O	1260	1265	weeks
O	1266	1270	with
O	1271	1273	O3
O	1273	1274	-
O	1274	1277	FAs
O	1278	1281	and
O	1282	1284	by
O	1285	1286	1
O	1286	1287	.
O	1287	1289	49
O	1290	1293	and
O	1294	1295	1
O	1295	1296	.
O	1296	1298	81
O	1299	1305	points
O	1305	1306	,
O	1307	1319	respectively
O	1319	1320	,
O	1321	1325	with
O	1326	1333	placebo
O	1333	1334	.

O	1335	1337	In
O	1338	1339	a
O	1340	1346	linear
O	1347	1357	regression
O	1358	1367	adjusting
O	1368	1371	for
O	1372	1375	the
B-outcome	1376	1384	baseline
I-outcome	1385	1390	score
O	1390	1391	,
B-outcome	1392	1406	osteoarthritis
O	1406	1407	,
O	1408	1411	and
B-outcome	1412	1418	taxane
I-outcome	1419	1422	use
O	1422	1423	,
O	1424	1432	adjusted
O	1433	1435	12
O	1435	1436	-
O	1436	1440	week
O	1441	1444	BPI
O	1444	1445	-
O	1445	1447	SF
O	1448	1454	scores
O	1455	1458	did
O	1459	1462	not
O	1463	1469	differ
O	1470	1472	by
O	1473	1476	arm
O	1477	1478	(
O	1478	1479	P
O	1480	1481	=
O	1482	1483	.
O	1483	1485	58
O	1485	1486	)
O	1486	1487	.

B-outcome	1488	1500	Triglyceride
I-outcome	1501	1507	levels
O	1508	1517	decreased
O	1518	1520	in
O	1521	1529	patients
O	1530	1539	receiving
O	1540	1542	O3
O	1542	1543	-
O	1543	1545	FA
O	1546	1555	treatment
O	1556	1559	and
O	1560	1568	remained
O	1569	1572	the
O	1573	1577	same
O	1578	1581	for
O	1582	1587	those
O	1588	1597	receiving
O	1598	1605	placebo
O	1606	1607	(
O	1607	1608	P
O	1609	1610	=
O	1611	1612	.
O	1612	1614	01
O	1614	1615	)
O	1615	1616	.

O	1617	1619	No
O	1620	1627	between
O	1627	1628	-
O	1628	1633	group
O	1634	1645	differences
O	1646	1650	were
O	1651	1655	seen
O	1656	1659	for
B-outcome	1660	1663	HDL
I-outcome	1663	1664	,
I-outcome	1665	1668	LDL
I-outcome	1668	1669	,
I-outcome	1670	1672	or
I-outcome	1673	1674	C
I-outcome	1674	1675	-
I-outcome	1675	1683	reactive
I-outcome	1684	1691	protein
O	1691	1692	.

O	1693	1695	We
O	1696	1701	found
O	1702	1703	a
O	1704	1715	substantial
O	1716	1717	(
O	1717	1718	>
O	1719	1721	50
O	1721	1722	%
O	1722	1723	)
O	1724	1727	and
O	1728	1737	sustained
O	1738	1749	improvement
O	1750	1752	in
O	1753	1755	AI
O	1756	1766	arthralgia
O	1767	1770	for
O	1771	1775	both
O	1776	1778	O3
O	1778	1779	-
O	1779	1782	FAs
O	1783	1786	and
O	1787	1794	placebo
O	1795	1798	but
O	1799	1804	found
O	1805	1807	no
O	1808	1818	meaningful
O	1819	1829	difference
O	1830	1837	between
O	1838	1841	the
O	1842	1848	groups
O	1848	1849	.
